Did NeuroOne Medical beat or miss consensus estimates last quarter?

What does NeuroOne Medical do and what are its main business segments?

What is the market's earnings forecast for NeuroOne Medical next quarter?

What is the revenue and EPS growth rate for NeuroOne Medical year over year?

What guidance did NeuroOne Medical's management provide for the next earnings period?

What were the key takeaways from NeuroOne Medical's earnings call?

What were the key takeaways from NeuroOne Medical’s earnings call?

What is NeuroOne Medical's latest dividend and current dividend yield?

- **Revenue Growth**: FY2026 sales target of $10.5 million (17% YoY), Q1 2026 sequential sales increase of 5.5%.
- **Product Adoption**: OneRF ablation system achieved nearly half of total cases since launch; trigeminal system treated 9 patients with 100% pain relief.
- **Strategic Momentum**: Drug delivery program accelerated to Q3 2026 launch; strategic partnership discussions for trigeminal system.
- **Financial Health**: Gross margin improved to 54.2%, cash position sufficient for FY2026 operations.
- **Pipeline Expansion**: Lower back pain programs in development, with advisory board formation and manufacturing partnerships.

**【CEO Summary Section】**
- Q1 2026 sales of $2.9 million, sequentially higher by 5.5% from Q4 2025, with FY2026 revenue projected at least $10.5 million (17% YoY increase).
- OneRF brain ablation system achieved nearly half of all ablations since launch in Q1 2026, with a notable success story of a pianist resuming his career post-ablation.
- Trigeminal nerve ablation system treated 9 patients across 3 centers, all reporting pain relief, with strategic partnership discussions underway.
- Drug delivery program accelerated, with devices expected in Q3 2026, and advisory board formation with oncology experts.
- Lower back pain management programs in development, including animal studies and manufacturing discussions.
- Appointment of Jason Mills to the Board, leveraging his strategic and investment banking expertise.

**【CFO Financial Commentary】**
- Product gross profit of $1.6 million (54.2% margin), up from $1.9 million (38.9% margin) in Q1 2025.
- Operating expenses of $3.3 million, with R&D at $1.4 million (up 16.7% YoY) and SG&A at $1.9 million (down 7.7% YoY).
- Net loss of $1.4 million, compared to net income of $1.8 million in Q1 2025, due to absence of one-time license revenue.
- Cash balance of $3.6 million as of December 2025, with sufficient funding through FY2026.

**【Q&A Highlights】**
- Trigeminal system adoption: 9 successful cases at 3 centers, with strategic partner in diligence phase.
- Zimmer responsible for all sales and marketing, with revenue primarily from restocking orders.
- R&D expenses expected to fluctuate, with drug delivery and spinal cord studies ramping up in H2 2026.
- Clinical feedback highlights ease of use and bedside procedure execution, with long-term outcomes tracked via registry.

NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Earnings Call Transcript

- **Record Growth**: 163% product revenue increase to $9.1M, 56.5% gross margin, and $8.2M capital raise in FY 2025.
- **FDA Milestones**: First successful OneRF trigeminal nerve ablation cases and FDA clearance for new pain management technologies.
- **Drug Delivery Breakthrough**: First preclinical sales to a major pharma company, with mid-2026 commercial readiness planned.
- **Cost Efficiency**: 5% YoY operating expense reduction and 71% net loss improvement.

**【CEO Opening Remarks】**
- Fiscal 2025 was record-breaking with 163% product revenue growth to $9.1M, 56.5% gross margin, and $8.2M capital raise.
- Key milestones: FDA clearance for OneRF trigeminal nerve ablation, first preclinical drug delivery sales, and ISO 13485 certification initiation.
- 2026 outlook: Commercial expansion of OneRF brain ablation via Zimmer Biomet, drug delivery device development, and basivertebral nerve ablation R&D.

**【CFO Financial Review】**
- Q4 2025 product revenue: $2.7M (907% YoY), gross margin: 55.8%, operating expenses down 2% to $2.9M.
- FY 2025 highlights: $9.1M product revenue (163% YoY), $5.1M gross profit (56.5%), $3.6M net loss (71% improvement).
- Cash position: $6.6M as of Q3 2025, sufficient funding through FY 2026.

**【Q&A Highlights】**
- **Trigeminal Nerve Ablation**: 2 successful patient cases in Q4, 3+ additional centers preparing for procedures.
- **Drug Delivery**: Mid-2026 shipments expected for preclinical testing with large pharma partner.
- **Registry Progress**: Epilepsy registry protocol finalized; enrollment expected Q2 2026.
- **Reimbursement**: Neurosurgeons using existing codes, no reported barriers to adoption.
- **Partnerships**: Exploring strategic collaborations for lower back pain technologies (paddle electrode and basivertebral nerve ablation).

NeuroOne Medical Technologies Corporation (NMTC) Q4 2025 Earnings Call Transcript

- **Revenue Surge**: Q3 product revenue up 105% to $1.7 million, with full-year guidance of $8-10 million (132%-190% YoY growth).
- **Margin Expansion**: Gross margin improved to 53.9%, with updated FY2025 target of 50-53%.
- **Patient Success**: First patient achieved 1-year seizure freedom, highlighting OneRF's clinical impact.
- **New Markets**: FDA 510(k) submitted for trigeminal neuralgia, and SCS electrode design targeting $3B lower back pain market.
- **Financial Strength**: Debt-free with $8 million cash, $8.2 million raised in April, and 46% net loss improvement.

**【CEO Summary Section】**
- **Revenue Growth**: Product revenue surged 105% to $1.7 million in Q3 FY2025, with gross margins improving to 53.9% (vs. 34.1% in Q3 FY2024). Full-year guidance updated to $8-10 million revenue (132%-190% YoY growth) and 50-53% gross margins.
- **Patient Outcomes**: Celebrated first patient achieving 1-year seizure freedom using OneRF ablation system, with plans for a post-market registry to track outcomes.
- **New Market Expansion**: 
  - Submitted FDA 510(k) for trigeminal neuralgia ablation, targeting 150,000 U.S. patients.
  - Developing basivertebral nerve ablation for lower back pain, with $3B annual market potential.
  - Received first order for drug delivery system from biotech partner, combining therapy and diagnostics.
- **Strategic Strengths**: Debt-free with $8 million cash, $8.2 million raised in April, and ISO 13485 certification underway for international expansion.
- **IP & Talent**: Secured first international patent for spinal cord stimulation electrode and hired Chief Medical Adviser Dr. Parag Patil.

**【CFO Financial Commentary】**
- **Q3 Financials**: 
  - Product revenue: $1.7 million (105% YoY growth).
  - Gross profit: $0.9 million (53.9% of revenue).
  - Operating expenses: $2.8 million (9% YoY decline).
  - Net loss: $1.5 million (46% improvement vs. Q3 FY2024).
- **Cash Position**: $8 million as of June 30, 2025 (vs. $1.5 million in Q3 FY2024), with $8.2 million raised in April.
- **Licensing Revenue**: $3 million in first 9 months of FY2025 from Zimmer Biomet agreement.

**【Q&A Key Highlights】**
- **Drug Delivery System**: In animal testing phase, with potential for human trials if successful.
- **Trigeminal Ablation**: Targeting neurosurgeons who already use OneRF for brain ablation, with 150,000 U.S. patients.
- **Spinal Cord Stimulation (SCS)**: Electrode design covers broader spine area, with multiple SKUs planned for different pain levels.
- **2026 Outlook**: No guidance yet, but funded through FY2026 with potential extension if milestones met.

NeuroOne Medical Technologies Corporation (NMTC) Q3 2025 Earnings Call Transcript

- **Massive Revenue Growth**: 97% YoY product revenue increase to $4.7M in H1 FY2025, driven by Zimmer Biomet partnership.
- **Margin Expansion**: Product gross margin doubles to 57.9%, with FY2025 guidance for 47-51% margin.
- **New Product Pipeline**: FDA-cleared trigeminal nerve ablation system targeting 150K annual US patients, with potential late 2025 launch.
- **Financial Strength**: $9.4M cash balance post-raise, no debt, fully funded through FY2026.
- **Clinical Validation**: 90%+ seizure-free rate in treated patients, with first patient now 12 months seizure-free.

**【CEO Summary Section】**
- Product revenue increased 97% YoY to $4.7 million in H1 FY2025, with product gross margin doubling to 57.9%.
- Secured $3 million upfront license payment from strategic partner Zimmer Biomet for exclusive US distribution rights.
- Launched OneRF trigeminal nerve ablation system for trigeminal neuralgia, with FDA 510(k) submission filed ahead of schedule.
- Expanded international expansion efforts with ISO 13485 certification process initiation.
- Reiterated FY2025 guidance: $8-10 million product revenue (132-190% YoY growth), 47-51% product gross margin.
- No debt; $8.2 million capital raise provides funding through FY2026.

**【CFO Financial Commentary】**
- Q2 FY2025 product revenue: $1.4 million (flat vs. Q2 FY2024), driven by initial Zimmer stocking order completion.
- H1 FY2025 product gross profit: $2.7 million (57.9% margin), up from $0.7 million (27.9% margin) in H1 FY2024.
- Total operating expenses down 4% to $6.7 million in H1 FY2025, with R&D and SG&A both decreasing 3-5%.
- Net loss narrowed to $0.5 million in H1 FY2025 vs. $6.2 million prior year, with cash balance at $1.3 million as of Q2 end.
- Post-call capital raise added $8.5 million, bringing total cash to $9.4 million as of April 2025.

**【Q&A Highlights】**
- 94% of FY2025 revenue expected to come from Zimmer Biomet partnership, with minimal direct sales to early adopters.
- Pro forma cash position: $9.4 million as of April 2025, fully funding operations through FY2026.
- New Chief Medical Advisor Dr. Parag Patil to lead clinical registry development and publications on OneRF seizure-free outcomes.
- Potential for additional revenue streams from spinal cord ablation and sEEG drug delivery partnerships in progress.

NeuroOne Medical Technologies (NMTC)-13 May 25-2025 Q2 Earnings call transcript

- **Record Growth**: Q1 2025 product revenue up 235% YoY to $3.3M, with gross margin tripling to 58.9%.
- **Zimmer Partnership Payoff**: $3M upfront payment and exclusive US distribution driving FY25 revenue guidance of $8-10M.
- **Clinical Impact**: 90%+ seizure-free rate in OneRF ablation patients, with one patient seizure-free for 9+ months.
- **FDA Momentum**: Trigeminal nerve ablation 510(k) submission expected Q2 2025, targeting late 2025 launch.

**【CEO Opening Remarks】**
- Q1 2025 Product Revenue: $3.3M (235% YoY growth) with 58.9% gross margin, up from $1M (27% margin) in Q1 2024.
- Expanded partnership with Zimmer Biomet: $3M upfront payment, exclusive US distribution for OneRF ablation system, and improved transfer pricing.
- Clinical success: 90%+ patients seizure-free post-OneRF procedure, with one patient seizure-free for 9+ months.
- FY25 Guidance: Product revenue $8-10M (132-190% YoY growth), gross margin 47-51%.

**【CFO Financial Highlights】**
- Total Q1 2025 Revenue: $6.3M (record high), including $3M license income from Zimmer.
- Operating expenses down 12% YoY to $3.2M, driven by R&D ($1.2M vs $1.5M) and SG&A ($2M vs $2.2M) savings.
- Net income: $1.8M ($0.06 EPS) vs $3.3M loss in Q1 2024.
- Cash balance: $1.1M as of Dec 31, 2024; no debt outstanding.

**【Key Q&A Takeaways】**
- **Gross Margin Sustainability**: 47-51% FY25 target achievable due to Zimmer partnership economics, though Q1 60% margin was anomalous.
- **FDA Trigeminal Nerve Ablation Submission**: 510(k) expected Q2 2025, with ~5-month review timeline based on prior experience.
- **Clinical Success Metric**: 1-year seizure-free rate is key benchmark, with current data showing strong early results.

NeuroOne Medical Technologies Corporation (NMTC) Q1 2025 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q4 2024 Earnings Call Transcript

NeuroOne Medical Technologies (NMTC)-14 Aug 24-2024 Q3 Earnings call transcript

NeuroOne Medical Technologies (NMTC)-14 May 24-2024 Q2 Earnings call transcript

NeuroOne Medical Technologies (NMTC)-13 Feb 24-2024 Q1 Earnings call transcript

NeuroOne Medical Technologies (NMTC)-14 Dec 23-2023 Q4 Earnings call transcript

NeuroOne Medical Technologies (NMTC)-14 Aug 23-2023 Q3 Earnings call transcript

NeuroOne Medical Technologies (NMTC)-11 May 23-2023 Q2 Earnings call transcript

NeuroOne Medical Technologies (NMTC)-14 Aug 22-2022 Q3 Earnings call transcript

NeuroOne Medical Technologies (NMTC)-14 May 22-2022 Q2 Earnings call transcript

NeuroOne Medical Technologies (NMTC)-14 Feb 22-2022 Q1 Earnings call transcript

NeuroOne Medical Technologies (NMTC)-15 Dec 21-2021 Q4 Earnings call transcript

- **Revenue Growth**: Q3 2021 product revenue $40K, collaboration $17K, up from $0 prior year.
- **Partnerships**: $2M upfront from Zimmer Biomet for sEEG electrodes; Mayo Clinic collaboration on electrode tech.
- **Product Milestones**: First human use of Evo cortical electrodes; sEEG electrodes targeting FDA clearance by end-2021.
- **Financial Health**: Net loss narrowed to $3M (vs. $7.1M prior year); $9M cash balance post-Nasdaq listing.
- **AI Opportunity**: Thin-film electrodes scalable for AI-driven therapies in complex neurological conditions.

**【CEO Opening Remarks】**
- Introduced NeuroOne as a leader in electrode technology for neurological treatments, emphasizing its platform for epilepsy, chronic pain, and Parkinson’s disease.
- Highlighted partnerships with the Mayo Clinic and Zimmer Biomet, with $2 million upfront payment from Zimmer for sEEG electrode development.
- Noted FDA clearance for Evo cortical electrodes and limited release in December 2020.
- Announced debt elimination and expansion to California for advanced electrode R&D.

**【CFO Financial Commentary】**
- Q3 2021 revenue: $40,000 (product) + $17,000 (collaboration), vs. $0 prior year.
- Operating expenses: $3M (vs. $1.6M prior year), driven by R&D ($2.1M vs. $1.1M) and SG&A ($0.9M vs. $0.5M).
- Net loss: $3M (vs. $7.1M prior year). Cash balance: $9M (vs. $4M at FY end 2020).
- No debt as of June 30, 2021.

**【CEO Product Updates】**
- **Diagnostics:**
  - Evo cortical electrodes used in first human case at Mayo Clinic, showing pre-seizure activity.
  - Evo sEEG depth electrodes expected for FDA clearance/commercialization by end-2021.
- **Therapeutics:**
  - Ablation electrodes to combine diagnostic and therapeutic functions, with animal studies in Q4 2021 and FDA submission in late 2022.
  - Chronic use electrodes for spinal cord stimulation targeting $3B+ chronic back pain market.
- **AI Potential:**
  - Scalable electrode design for thousands of contacts, enabling AI-driven treatments for paralysis and complex neurological conditions.
- **Milestones:**
  - Chronic use electrode accelerated aging testing by end-2021.
  - Advisory board formed with 6 leading neurosurgeons.
  - $12.5M institutional financing and Nasdaq listing completed.


Actual	-0.25	-0.18	-0.18	-0.19	-0.17	-0.08	-0.21	-0.2	-0.1711	-0.14	-0.11	-0.1	-0.11	0.06	-0.07	-0.03	-0.05	-0.03
Forecast		-0.235	-0.185	-0.2	-0.225	-0.11	-0.205	-0.205	-0.175	-0.14	-0.09	-0.09	-0.09	-0.1	-0.09	-0.05	-0.0362	-0.03
Surprise	0.00%	+23.40%	+2.70%	+5.00%	+24.44%	+27.27%	-2.44%	+2.44%	+2.23%	0.00%	-22.22%	-11.11%	-22.22%	+160.00%	+22.22%	+40.00%	-38.12%	0.00%

NMTC

NMTC fundamentals

NMTC Q1 2026 Earnings

Earnings Call

You can ask Aime

NMTC

NMTC fundamentals

NMTC Q1 2026 Earnings

Earnings Call

NMTC Earnings Call Summary for Q1/20268:30 AM on Feb 17, 2026

NMTC Earnings Call Summary for Q4/20258:30 AM on Dec 17, 2025

NMTC Earnings Call Summary for Q3/20258:30 AM on Aug 14, 2025

NMTC Earnings Call Summary for Q2/20258:30 AM on May 13, 2025

NMTC Earnings Call Summary for Q1/20258:00 AM on Feb 12, 2025

You can ask Aime